BIO Dec 2023 410.000 call
| Previous close | 108.00 |
| Open | 108.00 |
| Bid | 77.00 |
| Ask | 86.00 |
| Strike | 410.00 |
| Expiry date | 2023-12-15 |
| Day's range | 108.00 - 108.00 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Business Wire
Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
HERCULES, Calif., January 06, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the fourth quarter and full year 2022 on Thursday, February 16, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
- Zacks
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.
- Business Wire
Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference
HERCULES, Calif., January 04, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 4:30 p.m. Pacific Time. The presentation will be followed by a Q&A session with participation from Bio-Rad’s Executive Vice President and COO Andrew Last, and Execut
